Date,Title,Link,Status,Source
"""Nov 28, 2017""","""Gilead - Another Sobering Moment, But There Is\u00a0More""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://seekingalpha.com/article/4128199-gilead-another-sobering-moment&cid=52779693989983&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNEp3HVP_3jlmcsGaPRmb2FUEWtF_g""",1,"""Seeking Alpha"""
"""Nov 27, 2017""","""Buy Gilead Now And Get Kite For\u00a0'Free'""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://seekingalpha.com/article/4127915-buy-gilead-now-get-kite-free&cid=0&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNHcT80kCjRjMTvC32wI0KZ6p3nQRA""",2,"""Seeking Alpha"""
"""Nov 28, 2017""","""Gilead (GILD) Down 7.9% Since Earnings Report: Can It\u00a0Rebound?""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://finance.yahoo.com/news/gilead-gild-down-7-9-063906865.html&cid=52779693023259&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNEHRJAtUF2KD0D-s5t4G9VkC3giFQ""",3,"""Yahoo Finance"""
"""Nov 24, 2017""","""Gilead: Attractive After Big\u00a0Retreat?""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://seekingalpha.com/article/4127459-gilead-attractive-big-retreat&cid=0&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNG6z2DBJdRMsK_D8KMmyaR9IfF2uA""",4,"""Seeking Alpha"""
"""Nov 22, 2017""","""Gilead: Buying New\u00a0Growth""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://seekingalpha.com/article/4127114-gilead-buying-new-growth&cid=52779686415893&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNG7JLThy-vuUpJMleWf4boMFbaONg""",5,"""Seeking Alpha"""
"""Nov 2, 2017""","""What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in\u00a0October?""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.fool.com/investing/2017/11/02/whats-behind-gilead-sciences-incs-billion-slide-in.aspx&cid=52779659343715&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNEpKwf7oOOzstcZhd4hZhjJGSnzrA""",6,"""Motley Fool"""
"""Nov 15, 2017""","""Gilead Sciences Inc (GILD) President and CEO John F Milligan Sold $16 million\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.nasdaq.com/article/gilead-sciences-inc-gild-president-and-ceo-john-f-milligan-sold-16-million-of-shares-cm878680&cid=52779678374720&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNFAsACX2A7IkseZNd4_B6Qsb1rzLw""",7,"""Nasdaq"""
"""Nov 16, 2017""","""Watch Out Gilead, Juno's Strategy Might Just Pay\u00a0Off""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://seekingalpha.com/article/4125394-watch-gilead-junos-strategy-might-just-pay&cid=0&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNGPhcE3rh_HSlXX7iD49L37otHH2Q""",8,"""Seeking Alpha"""
"""Oct 31, 2017""","""Gilead Sciences: More Of The Same, Long Thesis\u00a0Holds""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://seekingalpha.com/article/4118367-gilead-sciences-long-thesis-holds&cid=52779655906207&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNFa0CkPMIC4ZDIjWbRYsUNCn4tkpQ""",Not Reachable,"""Seeking Alpha"""
"""Nov 15, 2017""","""Trade of the Day: Gilead Sciences, Inc.\u00a0(GILD)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://investorplace.com/2017/11/trade-day-gilead-sciences-inc-gild-2/&cid=52779675086587&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNG0-j0PdbftJJ9sFD9N7jCGGB8eDA""",9,"""Investorplace.com"""
"""Nov 18, 2017""","""The case for Gilead\u00a0Sciences""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.fool.com/investing/2017/11/18/better-buy-biogen-inc-vs-gilead-sciences.aspx&cid=52779681260343&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNHCJ_Iq3NUbn5-K1nc1vkzeFYvDrA""",10,"""Motley Fool"""
"""Nov 23, 2017""","""An Integrated BioSci Research On Gilead Sciences: Promising Dividends And\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://seekingalpha.com/article/4127291-integrated-biosci-research-gilead-sciences-promising-dividends-favorable-valuations&cid=52779684814549&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNFqqjPsHCHZLqnw6hUbUHZBV5wwtg""",Not Reachable,"""Seeking Alpha"""
"""19 hours ago""","""Another motive To buy these stock: Gilead Sciences, Inc. (GILD), Mondelez\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.stocknewsjournal.com/2017/11/29/another-motive-to-buy-these-stock-gilead-sciences-inc-gild-mondelez-international-inc-mdlz/&cid=52779690716855&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNF9pSYcneK-NSdRqW2Xck_YVBtM0Q""",11,"""StockNewsJournal"""
"""Nov 1, 2017""","""Gilead Is Persona Non\u00a0Grata""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://seekingalpha.com/article/4118998-gilead-persona-non-grata&cid=0&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNHVQ8D_zaaxMoIqgXazVJUtn6cN_g""",12,"""Seeking Alpha"""
"""Nov 14, 2017""","""Fort, Lp Buys CVS Health Corp, Omnicom Group Inc, Gilead Sciences Inc, Sells\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.nasdaq.com/article/fort-lp-buys-cvs-health-corp-omnicom-group-inc-gilead-sciences-inc-sells-anthem-inc-cm876793&cid=0&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNEryPS6hMh26BzPdh05UFREnoA3HA""",13,"""Nasdaq"""
"""Nov 27, 2017""","""Slumping Quant Score Make Gilead Sciences (GILD) a\u00a0Sell""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://investorplace.com/2017/11/slumping-quant-score-make-gilead-sciences-gild-a-sell/&cid=52779693524537&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNHoCel689GTlQii-5kOlvKEp8AT2w""",14,"""Investorplace.com"""
"""Nov 28, 2017""","""X-Chem and Gilead Announce Drug Discovery\u00a0Collaboration""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.businesswire.com/news/home/20171128005031/en/X-Chem-Gilead-Announce-Drug-Discovery-Collaboration&cid=52779694803467&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNEVI9-ZyGJ_H9TnAPWbqWGofdZZ-Q""",15,"""Business Wire (press release)"""
"""Nov 19, 2017""","""Gilead Sciences: Tapping Into The Vast China Market For\u00a0Growth""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://seekingalpha.com/article/4126248-gilead-sciences-tapping-vast-china-market-growth&cid=52779681017941&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNHncZvWHhvdmTaVy7_9eNlBIi-iDg""",Not Reachable,"""Seeking Alpha"""
"""14 hours ago""","""A Technical Strategy for Gilead Sciences, Inc. (GILD), CalAtlantic Group, Inc\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.allstocknews.com/2017/11/29/a-technical-strategy-for-gilead-sciences-inc-gild-calatlantic-group-inc-caa/&cid=52779693812794&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNEOVM_xGARGoapxMMExCmOdyy1j3A""",16,"""AllStockNews"""
"""Nov 28, 2017""","""Gilead Sciences, Inc. (GILD) Sees Large Decline in Short\u00a0Interest""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://ledgergazette.com/2017/11/28/gilead-sciences-inc-gild-short-interest-down-18-9-in-october.html&cid=52779690982514&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNGQnlvVB5HP-1uv1eQIDGE0B_TEpA""",Not Reachable,"""The Ledger Gazette"""
"""Nov 28, 2017""","""Gilead Slashes Price of Hepatitis C Drug for China\u00a0Launch""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.caixinglobal.com/2017-11-28/gilead-slashes-price-of-hepatitis-c-drug-for-china-launch-101177361.html&cid=52779694600501&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNFMmY6_h7_uLZKGBYU7FeQizwv38Q""",17,"""Caixin Global"""
"""16 hours ago""","""Examining Fresh Signals: Gilead Sciences, Inc. (GILD), T-Mobile US, Inc.\u00a0(TMUS)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://financialqz.com/2017/11/29/examining-fresh-signals-gilead-sciences-inc-gild-t-mobile-us-inc-tmus/&cid=52779693989983&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNEkuUciDEHXU3yRTYlt_L1Xnjz_7w""",18,"""Market Movers"""
"""19 hours ago""","""Analyzing Analysts' Recommendations \u2013 Gilead Sciences, Inc. (NASDAQ:\u00a0GILD)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.hotstockspoint.com/2017/11/analyzing-analysts-recommendations-gilead-sciences-inc-nasdaq-gild/&cid=52779696974539&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNGL7X4u0pdkemP8UMwMlzUrkff6mQ""",19,"""Hot Stocks Point"""
"""Nov 14, 2017""","""Dodge & Cox Buys Eli Lilly and Co, Micro Focus International PLC, Gilead\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.nasdaq.com/article/dodge-cox-buys-eli-lilly-and-co-micro-focus-international-plc-gilead-sciences-inc-cm877283&cid=0&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNEwRKitHScQSD7Hu9B1dHjmRInl4Q""",20,"""Nasdaq"""
"""18 hours ago""","""Where Does These Stocks Go From Here? \u2013 Gilead Sciences, Inc. (GILD), The\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://postanalyst.com/2017/11/29/where-does-these-stocks-go-from-here-gilead-sciences-inc-gild-the-procter-gamble-company-pg/&cid=52779694659294&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNFh9QuqP9vy9DBtULc8rk9rF5hxmQ""",21,"""Post Analyst"""
"""18 hours ago""","""Long Term Technical picture \u2013 Gilead Sciences, Inc.\u00a0(GILD)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.stocksgallery.com/2017/11/29/long-term-technical-picture-gilead-sciences-inc-gild/&cid=52779693379498&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNGhOSLX-84mYVohrezEE-mRs9A8Cg""",22,"""Stocks Gallery"""
"""Nov 9, 2017""","""You'll Be Stunned by Gilead Sciences CEO's Prediction for\u00a02018""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.fool.com/investing/2017/11/09/youll-be-stunned-by-gilead-sciences-ceos-predictio.aspx&cid=52779668641486&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNGvXmKBYW6PSaI69tYNfVYK4iB9Aw""",23,"""Motley Fool"""
"""25 minutes ago""","""Stocks making its way to the top \u2013 Gilead Sciences, Inc.\u00a0(GILD)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://news4j.com/2017/11/30/stocks-making-its-way-to-the-top-gilead-sciences-inc-gild/&cid=52779697720564&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNHCyMso_NRyrd2Rp6jPlvyRjHdOkQ""",24,"""The News Journal"""
"""Nov 24, 2017""","""Evaluating Insider Trading And Ownership For Gilead Sciences, Inc.\u00a0(GILD)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://economicsandmoney.com/2017/11/24/evaluating-insider-trading-and-ownership-for-gilead-sciences-inc-gild-2/&cid=52779687541686&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNH1ilggcgdMLCQQ9ChVtDP5Cdkm_g""",25,"""Economic News"""
"""Nov 6, 2017""","""Rating on Gilead Sciences (GILD) Stock Drops to\u00a0Sell""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://investorplace.com/2017/11/rating-on-gilead-sciences-gild-stock-drops-to-sell/&cid=52779665675398&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNFlEG9DXXaMf_HL4shTngsFEISEkg""",26,"""Investorplace.com"""
"""13 hours ago""","""Unusual Activity Spotted in Gilead Sciences Inc (GILD) and Positiveid Corp\u00a0(PSID)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://earlebusinessunion.com/unusual-activity-spotted-in-gilead-sciences-inc-gild-and-positiveid-corp-psid/460907/&cid=52779697260873&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNGP2jH_zgJER5NLr-hBfnPp9ondcQ""",27,"""The Business Union"""
"""Nov 1, 2017""","""Gilead Sciences, Inc. (GILD): What's the\u00a0Story?""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.stocknewsjournal.com/2017/11/15/gilead-sciences-inc-gild-whats-the-story-4/&cid=0&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNGE67DbVChzF7_g0waI7FxP5bdh7g""",28,"""StockNewsJournal"""
"""Nov 1, 2017""","""Taking a Look at the Data Behind Gilead Sciences, Inc.\u00a0(GILD)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.stocknewsjournal.com/2017/11/27/taking-a-look-at-the-data-behind-gilead-sciences-inc-gild-6/&cid=0&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNGPryWZ7wzrO6abQPC5PFhmqaLppg""",29,"""StockNewsJournal"""
"""13 hours ago""","""Gilead Sciences, Inc. (NASDAQ:GILD) \u2013 Investor's Roundup (P/E\u00a0Analysis)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://nasdaqjournal.com/index.php/2017/11/29/gilead-sciences-inc-nasdaqgild-investors-roundup-p-e-analysis/&cid=52779696379998&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNF3K4bzV18EIdtsP6KHqP6C8_3RTQ""",30,"""Nasdaq Journal (press release)"""
"""Nov 10, 2017""","""European advisory committee selected summary of opinions/actions -\u00a0November""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://seekingalpha.com/news/3311118-european-advisory-committee-selected-summary-opinions-actions-november&cid=52779670553897&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNGFMAcVskPYOqtjQCP9MyaddBciBw""",Not Reachable,"""Seeking Alpha"""
"""19 hours ago""","""Gilead Sciences Inc (GILD) Gordson Hollis Price Saturation Levels in\u00a0Focus""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://finnewsweek.com/gilead-sciences-inc-gild-gordson-hollis-price-saturation-levels-in-focus/561638/&cid=52779696303481&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNGXmihfbpbctuxVzoXl6iDyDSIRrQ""",31,"""Financial Newsweek"""
"""Nov 6, 2017""","""Few Things investors Didn't Know About: Gilead Sciences, Inc. (GILD), Rice\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://stocknewsjournal.com/2017/11/06/few-things-investors-didnt-know-about-gilead-sciences-inc-gild-rice-energy-inc-rice/&cid=52779665919290&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNExb3NqzU0mWZhBrPa9KIxi7OR65w""",32,"""StockNewsJournal"""
"""20 hours ago""","""Gilead Sciences, Inc. (GILD) Overcome Concerns on Long-Term\u00a0Commitments""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.stockmarketstop.com/gilead-sciences-inc-gild-overcome-concerns-on-long-term-commitments/875448/&cid=52779694683335&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNF1ovh2pJhJaua9EkZO9P_-143tRA""",33,"""Stock News Stop"""
"""Nov 29, 2017""","""Analysts assigned mean rating score of 2.40 for Gilead Sciences, Inc.\u00a0(GILD)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.wallstreetmorning.com/2017/11/29/analysts-assigned-mean-rating-score-of-2-40-for-gilead-sciences-inc-gild/&cid=52779696321018&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNHHAgAQeFPngGQAk9pDZVwXgHg-8w""",34,"""Wall Street Morning"""
"""Nov 9, 2017""","""Two stocks you should always put money on: Gilead Sciences, Inc. (GILD\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.stocknewsjournal.com/2017/11/09/two-stocks-you-should-always-put-money-on-gilead-sciences-inc-gild-harsco-corporation-hsc/&cid=52779665966040&ei=A94fWvitN4H2jAHvqKyoDw&usg=AFQjCNFRPBsAyzKRC7JuxkwO7aC0X_KySA""",35,"""StockNewsJournal"""
"""20 hours ago""","""Gilead Sciences, Inc. (GILD) Overcome Concerns on Long-Term\u00a0Commitments""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.stockmarketstop.com/gilead-sciences-inc-gild-overcome-concerns-on-long-term-commitments/875448/&cid=52779694733611&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNHWVaxOKmX91z9Hnoct22P3nOde_g""",36,"""Stock News Stop"""
"""13 hours ago""","""Unusual Activity Spotted in Gilead Sciences Inc (GILD) and Positiveid Corp\u00a0(PSID)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://earlebusinessunion.com/unusual-activity-spotted-in-gilead-sciences-inc-gild-and-positiveid-corp-psid/460907/&cid=52779696884587&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNFdfyNeW139ZdKaYTX_PzWLxsBjzQ""",37,"""The Business Union"""
"""Nov 9, 2017""","""Two stocks you should always put money on: Gilead Sciences, Inc. (GILD\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.stocknewsjournal.com/2017/11/09/two-stocks-you-should-always-put-money-on-gilead-sciences-inc-gild-harsco-corporation-hsc/&cid=52779665966040&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNHEjgF8oeZ3rQNEsbk9r62XsSoUmg""",38,"""StockNewsJournal"""
"""Nov 27, 2017""","""Analyst Hints Surrounding Live Nation Entertainment, Inc. (LYV) And Gilead\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://postanalyst.com/2017/11/27/analyst-hints-surrounding-live-nation-entertainment-inc-lyv-and-gilead-sciences-inc-gild/&cid=52779687350826&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNFQkwGHAmWVMjiAkp6cIUnKcArFAA""",39,"""Post Analyst"""
"""Nov 13, 2017""","""As Gilead's Outlook Dims, Argus\u00a0Downgrades""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.benzinga.com/analyst-ratings/analyst-color/17/11/10769949/as-gileads-outlook-dims-argus-downgrades&cid=52779671298430&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNFtV4h8MtNZJHadQbX0e_r8lZkpQQ""",40,"""Benzinga"""
"""Nov 29, 2017""","""Gilead Sciences Inc (GILD) AO Signal Trending\u00a0Upward""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.concordregister.com/gilead-sciences-inc-gild-ao-signal-trending-upward/&cid=0&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNEvAtzp7bPK54qdoKN7kFkUV6y7tg""",41,"""Concord Register"""
"""19 hours ago""","""Latest figures makes these Stock Even More Attractive: Gilead Sciences, Inc\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.tradingnewsnow.com/2017/11/29/latest-figures-makes-these-stock-even-more-attractive-gilead-sciences-inc-nasdaq-gild-rigel-pharmaceuticals-inc-nasdaq-rigl-lloyds-banking-group-plc-nyse-lyg-capital-one-financial/&cid=52779696442260&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNH0kl7V_NvhmeZQr8bX-Qz0TAHbxQ""",42,"""Stocks In The News (press release)"""
"""21 hours ago""","""Notable performer: Gilead Sciences, Inc. (GILD) stock price completes at $72\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.isstories.com/2017/11/29/notable-performer-gilead-sciences-inc-gild-stock-price-completes-at-72-59-with-change-of-1-24/&cid=52779696417948&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNFwmknqn9PN8cvKebY8kNJEhSuYXA""",43,"""Click Daily Finance"""
"""20 hours ago""","""Trading Sheet: Reviewing the Levels for Gilead Sciences, Inc.\u00a0(NasdaqGS:GILD)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://finnewsweek.com/trading-sheet-reviewing-the-levels-for-gilead-sciences-inc-nasdaqgsgild/561310/&cid=52779696485382&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNFZ5N3ul6doW8QPKQQXreKeb1UhAw""",44,"""Financial Newsweek"""
"""Nov 28, 2017""","""Recommended Stock:- Gilead Sciences, Inc. (NASDAQ:GILD) a Biotechnology\u00a0Company""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.thestreetpoint.com/2017/11/28/recommended-stock-gilead-sciences-inc-nasdaqgild-a-biotechnology-company/&cid=52779692761454&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNGBBC7DcqMwG7AR3Fgbbw1GmZ6rwQ""",45,"""The Stock Street (press release)"""
"""Nov 24, 2017""","""Analysts Are Gushing Over Microsoft Corporation (MSFT), Gilead Sciences, Inc\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.postanalyst.com/2017/11/24/analysts-are-gushing-over-microsoft-corporation-msft-gilead-sciences-inc-gild/&cid=0&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNFvNRNEHcgjtrRs2X8MHPQ0JbpEbA""",46,"""Post Analyst"""
"""19 hours ago""","""Gilead Sciences, Inc. (NASDAQ:GILD): Taking a Closer Look at This\u00a0Stock""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://mtnvnews.com/gilead-sciences-inc-nasdaqgild-taking-a-closer-look-at-this-stock/357518/&cid=52779695468544&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNFyQOgA8NjyJOGrr_rK97ycc2Qv1g""",47,"""MTNV"""
"""Nov 29, 2017""","""Can Gilead Sciences Inc (GILD) Go The Extra\u00a0Mile?""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://aikenadvocate.com/can-gilead-sciences-inc-gild-go-the-extra-mile/652455/&cid=52779694195643&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNFKwP1bMl77yy6SbgigoxQuyqZD9A""",48,"""Aiken Advocate"""
"""16 hours ago""","""Many Investors Taking a Second Look at Gilead Sciences, Inc. (NASDAQ:GILD\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://nlrnews.com/many-investors-taking-a-second-look-at-gilead-sciences-inc-nasdaqgild-after-recent-moves/370400/&cid=52779697537936&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNERoGj8sZxnJdOr4M4kyepGnj9enQ""",49,"""Nelson Research"""
"""Nov 28, 2017""","""Gilead Sciences, Inc. (GILD) is at $71.70 per share and CHF Solutions, Inc\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=http://www.stocksgallery.com/2017/11/28/gilead-sciences-inc-gild-is-at-71-70-per-share-and-chf-solutions-inc-chfs-is-listed-at-4-18/&cid=0&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNEIbQwLNzjI6WbwHQ2_ZziVxib7XA""",50,"""Stocks Gallery"""
"""21 hours ago""","""Are Gilead Sciences Inc. (GIS.DE) Shares Brimming\u00a0Over?""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://orobulletin.com/are-gilead-sciences-inc-gis-de-shares-brimming-over/351837/&cid=52779697391233&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNGiigqt-Sr64PJgbGdAYQd2IGFVag""",51,"""Bulletin News"""
"""20 hours ago""","""3 Dividend Stocks With Better Yields Than\u00a0McDonald's""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.fool.com/investing/2017/11/29/3-dividend-stocks-with-better-yields-than-mcdonald.aspx&cid=52779696367281&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNE71Vyv9dDGYWVAzkYWWnZbihPQGg""",52,"""Motley Fool"""
"""Nov 27, 2017""","""Gilead Sciences, Inc. (GILD)- Making Way Towards North with Performance\u00a0Booster""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://nasdaqtimes.com/gilead-sciences-inc-gild-making-way-towards-north-with-performance-booster/&cid=52779690779920&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNFcc8-2IRUCt3fSFWGio7vHkmMsZw""",53,"""NASDAQ Times"""
"""Nov 28, 2017""","""Closing Above PSAR Are Shares of Gilead Sciences Inc\u00a0(GILD)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://aikenadvocate.com/closing-above-psar-are-shares-of-gilead-sciences-inc-gild/652841/&cid=52779697758380&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNEGkuhXsTPGJwd9ZFhgg6TgFvykTA""",54,"""Aiken Advocate"""
"""Nov 29, 2017""","""Pounding the Pavement on Shares of Gilead Sciences, Inc.\u00a0(NasdaqGS:GILD)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://mtnvnews.com/pounding-the-pavement-on-shares-of-gilead-sciences-inc-nasdaqgsgild/356325/&cid=52779696285757&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNHBmGF_GC5gfHe7wPAFE1xBJnJP7g""",55,"""MTNV"""
"""Nov 27, 2017""","""Advice by Analysts to Buy Healthcare Stock: Gilead Sciences, Inc.\u00a0(GILD)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.streetobserver.com/2017/11/27/advice-by-analysts-to-buy-healthcare-stock-gilead-sciences-inc-gild/&cid=52779693955164&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNE_pbYwLqBPpPSMUlSUxSmO_WrQTQ""",56,"""Street Observer (press release)"""
"""14 hours ago""","""Technical Views: Tracking Shares of Gilead Sciences Inc\u00a0(GILD)""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://6milestandard.com/technical-views-tracking-shares-of-gilead-sciences-inc-gild/338947/&cid=52779697114675&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNGo4J8wZPD7FFdvftLu2-xVlAvxfQ""",57,"""The Standard"""
"""19 hours ago""","""Gilead Sciences, Inc. (GILD) Stocks Swing on Profitability Analysis- Meritor\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.investingbizz.com/2017/11/gilead-sciences-inc-gild-stocks-swing-on-profitability-analysis-meritor-inc-mtor/&cid=52779695968973&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNGaBADeWy2uPJq-hhNq_eY7BmeJmw""",58,"""Investing News Update"""
"""5 hours ago""","""Gilead Sciences Inc (GILD) Chaikin Money Flow Showing Positive\u00a0Signs""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://berryrecorder.com/gilead-sciences-inc-gild-chaikin-money-flow-showing-positive-signs/342014/&cid=52779697557257&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNFndYg-UWm9oTPtJsCLRVjwGIFcRA""",59,"""Berry Recorder"""
"""Nov 28, 2017""","""Is technical analysis on Gilead Sciences, Inc. (GILD) is\u00a0useful?""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.wallstreetmorning.com/2017/11/28/is-technical-analysis-on-gilead-sciences-inc-gild-is-useful/&cid=52779694857587&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNGSKcLz7ANQic-oVNXyg9JYqYEd9Q""",60,"""Wall Street Morning"""
"""15 hours ago""","""Technical Radar: SuperTrend Seen Above Stock Price for Gilead Sciences Inc\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://berryrecorder.com/technical-radar-supertrend-seen-above-stock-price-for-gilead-sciences-inc-gis-de/339274/&cid=52779696741570&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNGZ0pDVjIFSXJqezBA-Vs5N8Ojd0g""",61,"""Berry Recorder"""
"""Nov 27, 2017""","""Gilead Sciences, Inc. (GILD) Stock Price trades 0.49% off from 200-\u00a0SMA""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.analystsbuzz.com/2017/11/27/gilead-sciences-inc-gild-stock-price-trades-0-49-off-from-200-sma/&cid=52779694803435&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNGYYBADwHLkN2o0VlgTpe1XKdIoQg""",62,"""Voice Of Analysts"""
"""15 hours ago""","""Critical Profitability Ratio Analysis under Limelight: Gilead Sciences, Inc\u00a0...""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.senecaglobe.com/critical-profitability-ratio-analysis-under-limelight-gilead-sciences-inc-nasdaqgild-amerisourcebergen-corporation-nyseabc/385563/&cid=52779696675775&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNE8lqXix9VztxDbDgoRsGa5KFnrtg""",63,"""Seneca Globe"""
"""17 hours ago""","""Drug Charity May Shutter After US Faults Pharma\u00a0Influence""","""http://news.google.com/news/url?sa=T&ct2=us&fd=S&url=https://www.bloomberg.com/news/articles/2017-11-29/pharma-charity-may-shut-after-u-s-faults-drugmakers-influence&cid=52779696620074&ei=3d4fWrj1NIG02AaFhL-oCw&usg=AFQjCNGEgy92JoA24mboJ1Ag9wKTZ9eTRA""",64,"""Bloomberg"""
"""Nov 28, 2017""","""X-Chem And Gilead Announce Drug Discovery\u00a0Collaboration""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3721381&ei=Q98fWrD7JcSPjAG5hbEY&usg=AFQjCNEfMHXr8ticUTfdsRdcwRjvzUA6IQ""",Not Reachable,"""Reuters Key Development"""
"""Nov 15, 2017""","""Spring Bank Pharmaceuticals announces positive top-line results from the second cohort of part A of the phase 2 achieve\u00a0trial""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3714909&ei=Q98fWrD7JcSPjAG5hbEY&usg=AFQjCNFLiW5crpKeRcqgcTCGNzF3Jj6E1Q""",Not Reachable,"""Reuters Key Development"""
"""Nov 7, 2017""","""Gilead sciences says post-trial motions judge denied Idenix\u2019S motion for enhanced\u00a0damages""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3705514&ei=Q98fWrD7JcSPjAG5hbEY&usg=AFQjCNGt88IlYssNP2KgbD1YlabFiJTXlQ""",Not Reachable,"""Reuters Key Development"""
"""Oct 18, 2017""","""FDA approves Gilead's CAR-T cell\u00a0therapy""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3689706&ei=Q98fWrD7JcSPjAG5hbEY&usg=AFQjCNFW_nDDO_-DPZJ0Hlj5LbgVFJc6EA""",Not Reachable,"""Reuters Key Development"""
"""Sep 28, 2017""","""Kevin Young to retire as Gilead Sciences\u00a0COO""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3678943&ei=Q98fWrD7JcSPjAG5hbEY&usg=AFQjCNGSZFgloqJbpd4GvORsPvNF943USg""",Not Reachable,"""Reuters Key Development"""
"""Sep 25, 2017""","""Janssen submits new drug application to\u00a0FDA""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3677175&ei=Q98fWrD7JcSPjAG5hbEY&usg=AFQjCNEyA8z8pDHCDD1HwsSJRJ0b9NWOzQ""",Not Reachable,"""Reuters Key Development"""
"""Sep 21, 2017""","""Gilead Sciences says co entered into a seventh supplemental\u00a0indenture""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3676070&ei=Q98fWrD7JcSPjAG5hbEY&usg=AFQjCNGb4u6zN3S0-VSpIcu6gGiNI29qlg""",Not Reachable,"""Reuters Key Development"""
"""Sep 13, 2017""","""Gilead Sciences entered into a $6 bln term loan facility credit agreement - SEC\u00a0Filing""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3671910&ei=Q98fWrD7JcSPjAG5hbEY&usg=AFQjCNET42HaoUF9xVfcssIqs7ZxQPyw6w""",Not Reachable,"""Reuters Key Development"""
"""Aug 31, 2017""","""Gilead Sciences files for potential mixed shelf size not\u00a0disclosed""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3665784&ei=Q98fWrD7JcSPjAG5hbEY&usg=AFQjCNGN02SkdK2u_dvNN7o85eZG9s8YzQ""",Not Reachable,"""Reuters Key Development"""
"""Aug 28, 2017""","""Gilead Sciences to acquire Kite Pharma for $11.9\u00a0billion""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3661763&ei=Q98fWrD7JcSPjAG5hbEY&usg=AFQjCNGl4w9FDeC0cGBhNW9la4vkTsrZYA""",Not Reachable,"""Reuters Key Development"""
"""Aug 28, 2017""","""Gilead to buy Kite Pharma for roughly $11 billion in cash -\u00a0WSJ""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3661708&ei=Q98fWrD7JcSPjAG5hbEY&usg=AFQjCNHgPTfC6n3S5nRUgeSdDTP59C7BHA""",Not Reachable,"""Reuters Key Development"""
"""Aug 14, 2017""","""Temasek Holdings cuts share stake in Gilead\u00a0Sciences""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3652472&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNG7lTPTa830QA_NBXb6r9oejxN7IQ""",Not Reachable,"""Reuters Key Development"""
"""Aug 10, 2017""","""FDA grants priority status to Gilead's HIV\u00a0treatments""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3650070&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNHNB4DEpMpoI0rz9rLji5JhvNyFxg""",Not Reachable,"""Reuters Key Development"""
"""Jul 28, 2017""","""Gilead Sciences says European Commission grants marketing authorization for\u00a0Vosevi""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3638895&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNE7yGRuaLTQjhf7gRxu8rr_lEIW1w""",Not Reachable,"""Reuters Key Development"""
"""Jul 26, 2017""","""Gilead Sciences qtrly diluted earnings per share\u00a0$2.33""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3636427&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNEyR2q1gk6CK4DXI610Kiqf4oYHGg""",Not Reachable,"""Reuters Key Development"""
"""Jul 26, 2017""","""Mylan receives who prequalification for Generic\u00a0Sovaldi""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3636225&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNFQAdQr7ZpKJ-sTV57uv6cs8qT58g""",Not Reachable,"""Reuters Key Development"""
"""Jul 18, 2017""","""U.S. FDA approves Gilead\u2019s Vosevi for re-treatment of adults with chronic hepatitis C\u00a0virus""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3630967&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNH_R2bo3mxhQDtSACoPhLoVAfECcA""",Not Reachable,"""Reuters Key Development"""
"""Jul 10, 2017""","""Spring Bank Pharmaceuticals announces clinical trial collaboration with Gilead Sciences for clinical study examining SB\u00a09200""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3625469&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNGDrLUMt7IkfB7eUDc0btGp4K0Lgw""",Not Reachable,"""Reuters Key Development"""
"""Jun 23, 2017""","""European CHMP adopts positive opinion for Gilead's\u00a0Vosevi""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3617046&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNF4NPnIp_dEUTKXy7rd5wbJmT-H-w""",Not Reachable,"""Reuters Key Development"""
"""Jun 12, 2017""","""Gilead submits NDA for fixed-dose combination for HIV\u00a0treatment""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3610454&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNEBbe-6HqDg06DRG4r_dM9e1QkYKQ""",Not Reachable,"""Reuters Key Development"""
"""May 4, 2017""","""Gilead Sciences says Genvoya tablets, for HIV-1 treatment, is now listed in multiple provinces in\u00a0Canada""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3584388&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNH62W9fdd-s4jteIxBYlXiEf2MNNw""",Not Reachable,"""Reuters Key Development"""
"""Apr 21, 2017""","""Gilead announces results from 2 Phase 2 studies evaluating Harvoni tablets in chronic hepatitis C infected patient\u00a0populations""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3572882&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNHBcbWKdEOcaJs4L39mpcBDlqowrg""",Not Reachable,"""Reuters Key Development"""
"""Apr 7, 2017""","""FDA approves two of Gilead's hepatitis C drugs for pediatric\u00a0patients""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3564610&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNGJQrCjm20lDiJrB6zsIDDc_7N9Qw""",Not Reachable,"""Reuters Key Development"""
"""Mar 27, 2017""","""Gilead Sciences CEO John Milligan's 2016 total compensation was $13.9 mln- SEC\u00a0Filing""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3556104&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNG3Oui8AEFELO-zXRNs9OzbRhxhoA""",Not Reachable,"""Reuters Key Development"""
"""Mar 21, 2017""","""Gilead Sciences lists EPCLUSA on public drug plan to treat chronic hepatitis C\u00a0infection""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3552171&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNGBH9nF-KZP2-rdDBoYaI1xdgYHkA""",Not Reachable,"""Reuters Key Development"""
"""Mar 20, 2017""","""Gilead Sciences says EPCLUSA added to Liste des m\u00ef\u00bf\u00bddicaments de la\u00a0RAMQ""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3551077&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNEvfW1swpjP9xRvfzBJVoa8ULljEQ""",Not Reachable,"""Reuters Key Development"""
"""Mar 10, 2017""","""Galapagos announces two Phase 2 studies with filgotinib in small bowel and fistulizing Crohn's\u00a0disease""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3544574&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNE3o0-WT8ZPF7dz7xB4Gj2goUQzew""",Not Reachable,"""Reuters Key Development"""
"""Feb 22, 2017""","""Gilead Sciences Canada says Ontario to list Epclusa on public drug plan to treat all six genotypes of chronic Hepatitis C\u00a0infection""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3533070&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNG6Xt6dSeHH14sBfKSQyjrucQdoWQ""",Not Reachable,"""Reuters Key Development"""
"""Feb 16, 2017""","""Gilead receives approval in Canada for Odefsey for treatment of HIV-1\u00a0infection""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3529632&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNEPFUUKUFSvCl42St9C48Gq9XUN6Q""",Not Reachable,"""Reuters Key Development"""
"""Feb 16, 2017""","""AMYGDALA NEUROSCIENCES ACQUIRES GS-6637 FROM GILEAD\u00a0SCIENCES""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3529598&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNEfa0xTClkmRRTOlHUI9W-FeebHLQ""",Not Reachable,"""Reuters Key Development"""
"""Feb 7, 2017""","""Gilead Sciences sets quarterly dividend of $0.52 per\u00a0share""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3522141&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNExa4eh6NV3NwSzjD7uWXnYOrK92A""",Not Reachable,"""Reuters Key Development"""
"""Feb 7, 2017""","""Gilead Sciences reports Q4 earnings per share\u00a0$2.34""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3522142&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNExziLbSUB-u85VET2YMrely1gHKQ""",Not Reachable,"""Reuters Key Development"""
"""Jan 9, 2017""","""Gilead COO says slowdown in patients starting hep C therapies to continue in\u00a02017""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3505956&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNFVeK4TN4W1YaUmWLAsmZuylzjl2Q""",Not Reachable,"""Reuters Key Development"""
"""Dec 19, 2016""","""Gilead says Japan's Ministry of Health, Labour and Welfare approves co's Vemlidy for patients with chronic Hepatitis B virus\u00a0infection""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3497125&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNHMAFJOcXtWGT7I-nIKX306FKVxAw""",Not Reachable,"""Reuters Key Development"""
"""Dec 8, 2016""","""Gilead Sciences submits new drug application to U.S. FDA for Hepatitis\u00a0C""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3492215&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNFBtiblATA4UicAMlEHCPLGoOdIkg""",Not Reachable,"""Reuters Key Development"""
"""Dec 2, 2016""","""EMA says patients treated with direct-acting antivirals for hepatitis C may be at risk of hepatitis B\u00a0re-activation""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3489298&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNGX9iKX-NNJSRQ_2WN4nXpWk7WTHw""",Not Reachable,"""Reuters Key Development"""
"""Nov 17, 2016""","""GlobeImmune announces\u00a0updates""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3481082&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNFijfG6rjCTFAVbVchxKfCUVGYrnw""",Not Reachable,"""Reuters Key Development"""
"""Nov 14, 2016""","""Gilead - data for combination of selonsertib, gs-9674 in rodent model of advanced fibrosis resulted in greater anti-fibrotic activity than either agent\u00a0alone""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3478118&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNFLtggbSEOIyJhs_Q5BpwyX0ueunQ""",Not Reachable,"""Reuters Key Development"""
"""Nov 1, 2016""","""Gilead Q3 earnings per share\u00a0$2.49""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3467065&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNEHNuZ9rFEQ-JXGuA58KQ2wCP8wMA""",Not Reachable,"""Reuters Key Development"""
"""Oct 28, 2016""","""Galapagos Q3 net result turns to 8.1 mln euro\u00a0profit""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3463978&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNEy-QzGUVQllua4dSQAqHr3ZaDDPQ""",Not Reachable,"""Reuters Key Development"""
"""Sep 27, 2016""","""Gilead sciences, WHO announce 5-year visceral leishmaniasis\u00a0collaboration""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3445934&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNEjy041f-sZSexDodH7h7EiBEE4rA""",Not Reachable,"""Reuters Key Development"""
"""Sep 21, 2016""","""Gilead terminates phase 2/3 study of GS-5745 in patients with Ulcerative\u00a0Colitis""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3443702&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNGTU4xZfKs7LVpnlQDbriUsKgeFbw""",Not Reachable,"""Reuters Key Development"""
"""Sep 16, 2016""","""Gilead Sciences prices $5 bln of senior unsecured\u00a0notes""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3441667&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNFwJw0yUlse1XE2cBmgm73DASypfg""",Not Reachable,"""Reuters Key Development"""
"""Aug 10, 2016""","""Genmab enters commercial license agreement with Gilead for\u00a0DuoBody(R)Technology""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3423528&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNHcvw2ztjexdd-Xt2tFGuIHrByYDQ""",Not Reachable,"""Reuters Key Development"""
"""Aug 5, 2016""","""BRIEF-Massachusetts attorney general's office notifies Gilead of decision to suspend co's obligations under CID until further\u00a0notice""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3420629&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNEl3hizLG1-joRrMAIlIHGDNTZDdA""",Not Reachable,"""Reuters Key Development"""
"""Jul 25, 2016""","""Gilead Sciences sets qtrly dividend of $0.47 per\u00a0share""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3410920&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNEDkbRZr9QSFathdKkU-f477qOvtQ""",Not Reachable,"""Reuters Key Development"""
"""Jul 25, 2016""","""Gilead Sciences Q2 non-GAAP earnings per share\u00a0$3.08""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3410919&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNHBglS0IUzSRpCclXRlXZBbuxyeTA""",Not Reachable,"""Reuters Key Development"""
"""Jul 22, 2016""","""EMA adopts positive opinion on expanded approval of Gilead's HIV drug,\u00a0Truvada""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3410011&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNHwuMf5riAp2M742z1VNzdS2pAEiw""",Not Reachable,"""Reuters Key Development"""
"""Jul 21, 2016""","""Gilead's Odefsey meets primary objective in phase 3B\u00a0studies""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3409438&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNFoWgf5p8QScL6Eurjsqr6ZWvyQgg""",Not Reachable,"""Reuters Key Development"""
"""Jul 8, 2016""","""Ligand enters into Omniab platform license agreement with Gilead\u00a0Sciences""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3402421&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNF4HelLQ_nCWF3-kiYh-G5wabI3Dg""",Not Reachable,"""Reuters Key Development"""
"""Jun 28, 2016""","""Diplomat Pharmacy says to dispense epclusa for treatment of chronic Hepatitis\u00a0C""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3397233&ei=2N8fWpCnDcS6jAHwso7gBA&usg=AFQjCNE4MAEPmqXRkaYYlOGrc_K2HUbq0Q""",Not Reachable,"""Reuters Key Development"""
"""Jun 23, 2016""","""Gilead says European Commission grants marketing authorization for\u00a0Odefsey\u00ef\u00bf\u00bd""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3395263&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNHLFVss8SHiiMFE_cov02egtswRmA""",Not Reachable,"""Reuters Key Development"""
"""May 24, 2016""","""Gilead Sciences appoints Kevin Young as\u00a0COO""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3380848&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNEHOwry3n5L-cD82lqKSOZzcEQIRg""",Not Reachable,"""Reuters Key Development"""
"""May 24, 2016""","""Galapagos says completed end-of-Phase 2 FDA and EMA consultations in rheumatoid\u00a0arthritis""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3380837&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNHb-_uqtktJNv6mMkUIMab8Rbdn7g""",Not Reachable,"""Reuters Key Development"""
"""May 17, 2016""","""Galapagos listing of existing shares on Euronext Brussels &\u00a0Amsterdam""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3376436&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNEwGz4FWPv5Ckj1FT6P_-LOegyV4g""",Not Reachable,"""Reuters Key Development"""
"""Apr 28, 2016""","""Gilead Sciences, Inc announces quarterly\u00a0dividend""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3364854&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNEjOqdB4adPLfBV7_lza-YZrYqkhQ""",Not Reachable,"""Reuters Key Development"""
"""Apr 28, 2016""","""Gilead Sciences Inc reiterates FY 2016\u00a0guidance""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3365729&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNHolGG3HgniGQsDuk_JOT5qch3Wcw""",Not Reachable,"""Reuters Key Development"""
"""Apr 4, 2016""","""Gilead Sciences Inc says FDA approves\u00a0Descovy""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3352851&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNFE8ua4KTUJkISLdCry3mSsaEThgw""",Not Reachable,"""Reuters Key Development"""
"""Feb 16, 2016""","""Gilead Sciences says FDA approves two supplemental indications for Harvoni in chronic Hep C\u00a0patients""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3332038&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNHDHcw3M9ZKSj0OuLU6mNsGnUyA7A""",Not Reachable,"""Reuters Key Development"""
"""Feb 2, 2016""","""Gilead Sciences announces declaration of Q1 cash dividend and increases to shareholder return\u00a0programs""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3327627&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNFO3rO-OkdAzC_0VWW3WPtman9Cwg""",Not Reachable,"""Reuters Key Development"""
"""Jan 29, 2016""","""Gilead Sciences Inc's John C. Martin to assume role of Executive Chairman of the\u00a0Board""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3326041&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNFNSS-KXOHmKjEk5kyH2BAhDeSgJA""",Not Reachable,"""Reuters Key Development"""
"""Jan 25, 2016""","""Gilead holds 14.75% of Galapagos\u00a0shares""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3323408&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNGR1nbXSuq4BXDWRD2E-rb0FVcQAw""",Not Reachable,"""Reuters Key Development"""
"""Jan 13, 2016""","""Gilead and Galapagos global partnership cleared by U.S. Federal Trade Commission; Gilead to make equity investment in\u00a0Galapagos""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3320019&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNECH7lgQHsHVXdT90gY1Dz7aLdhCQ""",Not Reachable,"""Reuters Key Development"""
"""Jan 12, 2016""","""Gilead Sciences Inc submits new drug application for the treatment of chronic hepatitis\u00a0B""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3319660&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNEeXkymln5iMU2hW0Zyh0s3W_izBg""",Not Reachable,"""Reuters Key Development"""
"""Jan 5, 2016""","""Gilead Sciences Inc announces top-line results from two phase 3 studies evaluating tenofovir\u00a0alafenamide""","""//www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F3317720&ei=298fWtDuCtWEjAGEpImwDQ&usg=AFQjCNFBDE_YKVsHq50bRePv-8K--HModA""",Not Reachable,"""Reuters Key Development"""
